Loading...
XWAR
BIO
Market cap94mUSD
Dec 05, Last price  
4.00PLN
1D
1.78%
1Q
-4.53%
Jan 2017
-51.04%
IPO
-89.00%
Name

Bioton SA

Chart & Performance

D1W1MN
XWAR:BIO chart
P/E
—
P/S
1.65
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
0.56%
Revenues
208m
+14.38%
151,586,000215,479,000270,942,000293,517,000286,228,000378,595,000288,984,000406,303,000340,358,000377,303,000404,408,000277,613,000361,649,000241,166,000202,032,000221,788,000163,034,000233,159,000181,636,000207,763,000
Net income
-16m
L
34,627,00092,698,00026,572,000-223,033,000-599,878,000110,726,000-83,936,00037,837,000-6,443,0003,678,000-522,855,000-28,567,000-7,266,00026,266,000-126,693,00033,920,0002,882,0001,421,0002,275,000-15,658,000
CFO
36m
-8.32%
7,127,000-10,763,000-530,00037,745,000-80,222,00027,170,000-22,200,000144,796,00079,963,00041,874,00024,023,00023,146,00017,503,00027,880,00046,707,00041,949,0005,522,00056,082,00039,625,00036,330,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, medications, and other pharmaceutical products in Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. The company offers recombinant human and classic insulin; oral anti-diabetic medication products; dietary supplements; strips for measuring sugar in blood, as well as OTC preparation for diabetics; diabetics drugs insulin vials and cartridges, including Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. It engages in advertising, advisory, and company management activities. The company was founded in 1989 and is based in Ozarów Mazowiecki, Poland.
URL
https://bioton.com/
IPO date
Mar 16, 2005
Employees
355
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT